Global clinical trials activity decreases 1% in Q1 2021 over 4Q average - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Global clinical trials activity decreases 1% in Q1 2021 over 4Q average

05 May 2021 (Last Updated May 5th, 2021 21:12)

The global clinical trials activity saw a decrease of 1% in Q1 2021, when compared with the rolling average of the last four quarters (Q1 2020 to Q4 2020), according to GlobalData.

Of the overall activity, industry sponsored trials accounted for a 51.5% share in Q1 2021, marking an increase of 3.6% in the total share when compared with the four-quarter average.

Non-industry sponsored trials accounted for a 48.5% share of all the clinical trials globally in Q1 2021, marking a decrease of 3.6% in the overall share when compared with the four-quarter average.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

 

Top therapy areas for industry and non-industry sponsored clinical trials in Q1 2021

Oncology was the leading therapy area for industry sponsored clinical trials in Q1 2021, accounting for a 29.7% share of all trials.

This was followed by the following therapy areas: Infectious Disease with an 18.4% share, Central Nervous System with a 13.3% share, Metabolic Disorders with a 7.3% share and Cardiovascular with a 6.4% share.

In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 26.2% share, followed by Infectious Disease with a 21.2% share, Central Nervous System with a 12.6% share, Respiratory with a 9.3% share, and Metabolic Disorders with a 7.8% share.

Industry sponsored trials activity: 4-Quarter Avg. vs Q1 2021
Therapy Area 4-Quarter Avg. Q1 2021 Activity
Oncology 26.2% 29.7% Increase
Infectious Disease 21.2% 18.4% Decrease
Central Nervous System 12.6% 13.3% Increase
Metabolic Disorders 7.8% 7.3% Decrease
Cardiovascular 7.5% 6.4% Decrease
Respiratory 9.3% 5.8% Decrease
Gastrointestinal 6.4% 5.3% Decrease
Immunology 5.1% 5.1% Decrease
Musculoskeletal Disorders 3.5% 3.8% Increase
Dermatology 4.3% 3.3% Decrease
Ophthalmology 2.7% 3.3% Increase
Hematological Disorders 3.0% 3.1% Increase
Genito Urinary System And Sex Hormones 2.7% 2.2% Decrease
Genetic Disorders 1.5% 1.5% Decrease
Women’s Health 1.8% 1.4% Decrease
Ear Nose Throat Disorders 1.5% 1.0% Decrease
Male Health 0.9% 0.7% Decrease
Hormonal Disorders 0.5% 0.6% Increase
Mouth and Dental Disorders 0.5% 0.5% Decrease
Nutritional Disorders 0.4% 0.5% Increase
Non Malignant Disorders 0.2% 0.0% Decrease

 

Oncology was the leading therapy area for non-industry sponsored clinical trials in Q1 2021, accounting for a 27.8% share of all trials.

This was followed by the following therapy areas: Central Nervous System with a 24.8% share, Infectious Disease with a 16.8% share, Cardiovascular with a 9.3% share, and Musculoskeletal Disorders with a 5.0% share.

In the last four quarters, Infectious Disease System held a lead over others for non-industry sponsored clinical trials with an average share of 23.6%, followed by Oncology with a 22.2% share, Central Nervous System with a 20.4% share, Respiratory with an 8.9% share, and Cardiovascular with an 8.3% share.

Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q1 2021
Therapy Area 4-Quarter Avg. Q1 2021 Activity
Oncology 22.2% 27.8% Increase
Central Nervous System 20.4% 24.8% Increase
Infectious Disease 23.6% 16.8% Decrease
Cardiovascular 8.3% 9.3% Increase
Musculoskeletal Disorders 4.3% 5.0% Increase
Gastrointestinal 6.0% 4.7% Decrease
Respiratory 8.9% 4.6% Decrease
Metabolic Disorders 4.8% 4.5% Decrease
Immunology 2.8% 3.0% Increase
Women’s Health 4.4% 3.0% Decrease
Hematological Disorders 2.8% 2.9% Increase
Genito Urinary System And Sex Hormones 2.7% 2.5% Decrease
Dermatology 2.6% 1.8% Decrease
Mouth and Dental Disorders 1.9% 1.7% Decrease
Ophthalmology 1.4% 1.7% Increase
Ear Nose Throat Disorders 1.1% 0.9% Decrease
Hormonal Disorders 0.6% 0.7% Increase
Genetic Disorders 0.5% 0.6% Increase
Nutritional Disorders 0.7% 0.6% Decrease
Male Health 0.5% 0.5% Decrease
Non Malignant Disorders 0.4% 0.4% Decrease

 

Top regions in industry and non-industry sponsored clinical trials activity in Q1 2021

Asia-Pacific held the top position for industry sponsored clinical trials activity in Q1 2021 with a 46.7% share, compared to 53.8% in the last four quarters.

North America stood at second place with a 38.1% share in Q1 2021, over 31.6% in the last four quarters, followed by Europe with a 29.5% share in Q1 2021, as against 28.1% in the last four quarters.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held an 83.6% share in industry sponsored clinical trials in Q1 2021 when compared with 84.3% of average recorded in the last four quarters. Multinational trials accounted for a 16.4% share in Q1 2021, as against the four-quarter average of 15.7%.

Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q1 2021 with a 39.4% share, over 47.9% in the last four quarters.

North America held the second position with a 27.6% share in Q1 2021, over 17.3% in the last four quarters, followed by Europe with a 20.2% share in Q1 2021, as against 15.3% in the last four quarters.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held a 98.7% share for non-industry sponsored clinical trials in Q1 2021, compared to 98.8% in the last four quarters. Multinational trials accounted for a 1.3% share in Q1 2021, as against 1.2% in the last four quarters.

Industry and industry sponsored clinical trials by Phase in Q1 2021

Phase II trials outnumbered all other studies with a 39.7% share for industry sponsored trials in Q1 2021, compared to 34.6% average in the last four quarters.

The share of Phase I trials stood at 30.9% in Q1 2021, as against the four-quarter average of 36.4%. Phase III trials held an 18.0% share in Q1 2021, registering an increase of 0.9% over the last four quarters average, followed by Phase IV trials with an 11.4% share in Q1 2021, as against the four-quarter average of 11.9%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials outnumbered all other trials with a 49.5% share for non-industry sponsored clinical trials in Q1 2021, compared to 43.9% in the last four quarters.

Phase IV trials stood at second place with a 21.4% share in Q1 2021, compared to 19.4% in the last four quarters. Phase I trials held a 14.5% share in Q1 2021, as against 16.0% in the last four quarters, followed by Phase III trials with a 14.5% share in Q1 2021 over 20.8% average recorded in the last four quarters.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.
    Methodology:

    The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.